Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Aiforia H2’25: Green shoots on the clinical side

Aiforia Technologies

Aiforia’s H2 revenue growth originated in Europe, where the company has successfully promoted the adoption of clinical models. The digital pathology market has developed more slowly than expected, and the investment's risk profile remains high. Analyst Antti Siltanen summarizes.

Stay up to date
Analyst Interviews

Recent videos

Aiforia H2’25: Green shoots on the clinical side
16.03.2026, 10.29 Aiforia Technologies
HCA Morgenbørs 16/03 - Fokus på bl.a. GN store Nord efter salg af Hearing
16.03.2026, 09.38 GN Store Nord
HCA Morgenbørs 13/03 - Afventende markeder op til weekenden
13.03.2026, 11.53 DSV
Rapala H2'25: North American sales a highlight of the end of the year
12.03.2026, 16.25 Rapala VMC
Columbus – Presentation of Annual Report 2025
12.03.2026, 13.00 Columbus
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.